Clinical Study

A Randomized Double-Blind Phase III Study Of Ibrutinib During And Following Autologous Stem Cell Transplantation Versus Placebo In Patients With Relap

Posted Date: May 15, 2019

  • Investigator: Tahir Latif
  • Specialties:
  • Type of Study: Drug

Alliance A051301

Criteria:

To Be Eligible To Participate In This Study, Patients Must Have A Certain Type Of Diffuse Large B-Ce

Keywords:

A051301, Cancer, Lymphoma, Phase Iii

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.